0001209191-18-047860.txt : 20180821
0001209191-18-047860.hdr.sgml : 20180821
20180821194259
ACCESSION NUMBER: 0001209191-18-047860
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20180821
FILED AS OF DATE: 20180821
DATE AS OF CHANGE: 20180821
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: WANG JUNFENG
CENTRAL INDEX KEY: 0001748417
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38613
FILM NUMBER: 181031226
MAIL ADDRESS:
STREET 1: C/O CHARLES WU, LEGEND CAPITAL, 10F, TO
STREET 2: RAYCOM INFOTECH PARK, NO.2 KEXUEYUAN SOU
CITY: ZHONGGUANCUN HAIDIAN DISTRICT,
STATE: F4
ZIP: 100190
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BioNano Genomics, Inc
CENTRAL INDEX KEY: 0001411690
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
BUSINESS ADDRESS:
STREET 1: 9640 TOWNE CENTRE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: (858) 888-7600
MAIL ADDRESS:
STREET 1: 9640 TOWNE CENTRE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: BioNanomatrix Inc
DATE OF NAME CHANGE: 20070906
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2018-08-21
0
0001411690
BioNano Genomics, Inc
BNGO
0001748417
WANG JUNFENG
C/O BIONANO GENOMICS, INC.
9640 TOWNE CENTRE DRIVE, SUITE 100
SAN DIEGO
CA
92121
1
0
1
0
Series C Convertible Preferred Stock
0.00
Common Stock
8545184
I
By entities affiliated with LC Fund VI, L.P.
Series D Convertible Preferred Stock
0.00
Common Stock
6443565
I
By entities affiliated with LC Fund VI, L.P.
Series D-1 Convertible Preferred Stock
0.00
Common Stock
27305708
I
By entities affiliated with LC Fund VI, L.P.
Series D Convertible Preferred Stock Warrants (Right to Buy)
0.41
2016-03-04
2026-03-04
Series D Convertible Preferred Stock
11263624
I
By entities affiliated with LC Fund VI, L.P.
The convertible preferred stock is convertible at any time at the holder's election and automatically converts upon the consummation of a qualified public offering of the registrant. There is no expiration date for any series of preferred stock.
The shares are held as follows: 8,203,376 shares held by LC Fund VI, L.P. ("LC Fund") and 341,808 shares held by LC Parallel Fund VI, L.P. ("Parallel Fund") LC Fund and Parallel Fund are controlled and managed by Legend Capital, a limited liability Chinese company. The Reporting Person is a Managing Director of Legend Capital. The Reporting Person disclaims beneficial ownership with respect to these securities, except to the extent of his pecuniary interest therein.
The shares are held as follows: 6,143,224 shares held by LC Fund and 300,341 shares held by Parallel Fund. LC Fund and Parallel Fund are controlled and managed by Legend Capital, a limited liability Chinese company. The Reporting Person is a Managing Director of Legend Capital. The Reporting Person disclaims beneficial ownership with respect to these securities, except to the extent of his pecuniary interest therein.
The shares are held as follows: 3,924,722 shares held by LC Fund, 241,948 shares held by Parallel Fund and 23,139,038 shares held by LC Healthcare Fund I, L.P. ("Healthcare Fund"). LC Fund, Parallel Fund and Healthcare Fund are controlled and managed by Legend Capital, a limited liability Chinese company. The Reporting Person is a Managing Director of Legend Capital. The Reporting Person disclaims beneficial ownership with respect to these securities, except to the extent of his pecuniary interest therein.
The warrants are held as follows: warrant to purchase 10,738,615 shares held by LC Fund and warrant to purchase 525,009 shares held by Parallel Fund. LC Fund and Parallel Fund are controlled and managed by Legend Capital, a limited liability Chinese company. The Reporting Person is a Managing Director of Legend Capital. The Reporting Person disclaims beneficial ownership with respect to these securities, except to the extent of his pecuniary interest therein.
/s/ Heather Adams, Attorney-in-Fact
2018-08-21
EX-24.3_806508
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
Know all, by these presents, that the undersigned hereby constitutes and
appoints each of R. Erik Holmlin, Michael Ward and Heather Adams, signing
individually, the undersigned's true and lawful attorneys-in fact and agents to:
(1) execute for and on behalf of the undersigned, an officer, director or holder
of 10% of more of a registered class of securities of BioNano Genomics, Inc.
(the "Company"), Forms 3, 4 and 5 in accordance with Section 16(a) of the
Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules
thereunder;
(2) do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to complete and execute such Form 3, 4 or 5,
complete and execute any amendment or amendments thereto, and timely file such
forms or amendments with the United States Securities and Exchange Commission
and any stock exchange or similar authority; and
(3) take any other action of any nature whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in
the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the earliest
to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5
with respect to the undersigned's holdings of and transactions in securities
issued by the Company, (b) revocation by the undersigned in a signed writing
delivered to the foregoing attorneys-in-fact or (c) as to any attorney-in-fact
individually, until such attorney-in-fact shall no longer be employed by the
Company.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 19th day of July, 2018.
/s/ Junfeng Wang